There are multiple hypotheses for the etiology of neuropathic pain originating in different parts of the central and peripheral nervous systems.
Development
A European meta-analysis looked at the development of neuropathic pain in the setting of a recent SCI [
50]. Over 1000 individuals were screened with a European Multi-Center Study about Spinal Cord Injury (EMSCI) pain questionnaire 1 month after injury and had their pain status assessed at 6 months and 12 months [
50]. Risk factors for developing neuropathic pain at any time point following SCI were advanced age and motor and sensory preservation following less severe injury [
50]. At the initial visit 27% of patients had neuropathic pain; 23% of patients who initially screened negative developed pain at either the 6- or 12-month follow-up [
50]. Interestingly, 30% of patients that initially presented with pain saw resolution over the course of the 12-month period [
50]. Thus, approximately 35% of initially screened patients with SCI had neuropathic pain at the 12-month checkpoint [
50]. While the pathophysiology of delayed development of neuropathic pain is not well understood, it is likely that the delay reflects time required for neuroma development [
50]. This study demonstrated the importance of long-term follow-up both in patients presenting with and those presenting without symptoms immediately after SCI [
50].
Recent studies have shed light on neurological deficit associated with SCI results not only from direct tissue damage but also from the inflammatory response that develops in the weeks following injury [
51]. The alpha 7 nicotinic acetylcholine receptor (α7-nAChR) plays a central role in downregulating inflammatory responses [
51]. The α7-nAChR is encoded by the
CHRNA7 gene, which in some individuals is fused with a partial duplication of gene
FAM7A to create
CHRFAM7A [
51]. Individuals with the del2bp gene variant polymorphism of
CHRFAM7A encode a protein called dupΔα7, which suppresses α7-nAChR function and induces a pro-inflammatory phenotype [
51]. When α7-nAChR is suppressed, levels of pro-inflammatory cytokines such as TNFα are thought to increase [
51]. Huang and colleagues analyzed how the presence of
CHRFAM7A contributes to outcomes after SCI [
51]. When levels of noradrenergic metabolites and circulating cytokines were measured in patients with SCI and compared to controls, TNFα levels were found to be three times higher in patients with the del2bp gene variant compared to no deletion genotypes 3 weeks after injury [
51]. Noradrenergic metabolite levels were unchanged immediately after injury but significantly decreased in carriers of the deletion 3 weeks following injury compared to non-carriers [
51]. Interestingly, numeric pain scores in patients with the deletion were significantly higher compared to those without the gene variant [
51].
In continuing the molecular approach to the post-SCI inflammatory response, gap junction (GJ) channels, specifically connexin43 (Cx43), have been implicated in the development of neuropathic pain [
52]. Cx43 is the most abundant connexin in mammals and is most commonly expressed in astrocytic glial cells of the central nervous system [
52]. While neuropathic pain treatments have traditionally focused on neurons, new disease models suggesting that Cx43 expression increases after SCI are now shifting the focus to glial cells [
52]. It is thought that following nerve injury, upregulation of GJs and Cx43 causes sensitization of glial cells to pain media such as ATP and other inflammatory cytokines, resulting in increased synaptic pain signaling [
52]. Of note, the functionality of connexins also includes extracellular exchange via unpaired hemichannels [
53]. These specific hemichannels have been targeted by short peptides called peptidomimetics that act on components of the connexin pathways and ultimately prevent hemichannel opening. In rat models, these peptidomimetics have proven successful in reducing neuroinflammation after SCI [
53]. With increased specificity, hemichannels can be targeted without inhibition of GJs using peptidomimetics, directed antibodies, or non-peptide analogues of connexin mimetic peptides. Further investigation is required to better understand the mechanism by which Cx43 and its hemichannel are involved in the pathogenesis of neuropathic pain to pave the way for future therapeutic strategies [
52].
Treatment
Various medications have been assessed for their potential to reduce the intensity of neuropathic pain of various etiologies. First-line pharmacologic interventions for treatment of neuropathic main include gabapentinoids, TCAs, selective serotonin reuptake inhibitors (SSRIs), and SNRIs [
56]. Unfortunately, controversy exists regarding the efficacy of even these first-line agents. Studies have suggested that there may be lack of evidence regarding successful treatment with amitriptyline, but this conclusion must be balanced against the many patients who have achieved pain relief with this drug [
57]. In a case report of a patient with central neuropathic pain secondary to a diffuse glioma and refractory to these medications, the patient subsequently achieved adequate pain control on gabapentin, methadone, and high-dose oxycodone [
56]. While many patients rely on opioids for pain control, the known risks associated with this class of drugs begs for further research into safer treatment options for neuropathic pain.
Another case report describes a 58-year-old patient who suffered a traumatic SCI in Spain; his injury also proved refractory to the aforementioned first-line agents [
58]. He tried experimental treatments such as celiac plexus stimulation and neuromodulation to no avail [
58]. Moderate results were achieved using hypnosis from a qualified psychiatrist with overall pain levels decreasing from a numeric rating scale (NRS) 7 to an NRS 5 [
58]. While this case report illustrates the success of hypnotic intervention in a single patient, it exemplifies the lengths to which individuals will go for even marginal results.
In patients with neuropathic pain secondary to traumatic injury causing central cord syndrome refractory to conventional analgesics, a group of orthopedists in China examined the effect of treatment with methylprednisolone on acute neuropathic pain [
59]. In a small sample of 34 patients that was not placebo controlled, patients received seven methylprednisolone infusions daily for 1 week [
59]. Allodynia relief exceeding 50% was seen in 91% of patients during the 3-month follow-up period [
59]. A separate hypothesis included a small, 13-subject, placebo-controlled study that used intrathecal baclofen as an intervention to improve neuropathic pain. Baclofen, a GABA analogue, has been previously shown to exert antinociceptive effects [
60]. A single bolus of baclofen was administered after treatment randomization and was observed to result in a significant decrease in neuropathic pain at the 4- and 8-h marks, but not the 24-h mark [
61]. The baclofen bolus was also associated with a significant decrease in spasticity at the 4-h mark, suggesting that it could be used as an acute intervention [
61]. Further, it improved quality of life by decreasing the interference of chronic pain in the daily lives of affected patients [
61]. In a French study, the use of ziconotide, an omega-conotoxin analogue that blocks neuronal N-type voltage-sensitive calcium channels, was examined in 20 patients [
62]. After an intrathecal injection of ziconotide, 14 of 20 patients had decreases in pain scores greater than 40% [
62]. Three of the 14 patients experienced side effects [
62]. Two of the patients had serum creatine phosphokinase (CPK) elevations to greater than 3000 μg/L and were immediately withdrawn from treatment; the other patient experienced acute urinary retention and voluntarily withdrew from the study [
62]. The remaining 11 of 14 responders opted to have permanent ziconotide pumps implanted [
62]. In eight of these 11 patients, the analgesic effect persisted for an average follow-up of over 3 years [
62]. The promising effects of methylprednisolone, baclofen, and ziconotide on neuropathic pain should be subject to further exploration.
A Brazilian research group examined two separate areas of the brain as potential targets for central stimulatory therapy [
63]. Ninety-eight patients of various ages with clinically diagnosed central neuropathic pain were chosen as subjects for transcranial magnetic stimulation (TMS) of either the ACC or the posterior superior insula (PSI) [
63]. These patients underwent repetitive TMS over the course of 16 sessions over 12 weeks [
63]. TMS has demonstrated promise in the treatment of fibromyalgia, complex regional pain syndrome, and peripheral neuropathic pain and is believed to act by influencing blood flow and neurotransmitter release [
63]. This double-blind study featured a control group receiving placebo stimulation [
63]. While pain scores were not significantly different between the two groups, activation of the PSI induced analgesia while activation of the ACC had anxiolytic effects [
63]. This observation suggests a proof of concept of a biological response to TMS; the observed significant differences suggest that the framework used in this study provides a method for future research [
63].
Transcranial direct current stimulation (tDCS) is an alternative to TMS whose application has also been tested for the reduction of neuropathic pain in patients post-SCI. Thibaut and colleagues assessed the initial and long-term effects of tDCS directed at the primary motor cortex (M1) on pain (visual analogue scale, VAS), quality of life (Patient Health Questionnaire, PHQ-9), and life satisfaction (Satisfaction with Life Scale, SWLS) [
55]. M1 was the chosen target given its role in central pain modulation and evidence that M1 stimulation leads to local and distant pain reduction [
55]. Patients had the option of enrolling in one or two phases of the randomized controlled study [
55]. In the first phase, patients underwent 5 days of tDCS with 3 months of follow-up while in the second phase tDCS was performed for 10 days with 8 weeks of follow-up [
55]. Significantly reduced pain was observed at 1 week of follow-up in phase 1 and at 4 weeks in phase 2 [
55]. This delay in tDCS effects indicates that the resultant reduction in pain is caused by changes in cortical plasticity rather than immediate changes in excitability [
55]. These finding indicate that tDCS, while a promising tool for managing pain in patients with SCI, requires an optimized treatment protocol with repeated stimulation sessions to achieve long-lasting reduction in pain [
55].
Another potential novel treatment for neuropathic pain utilizes breathing-controlled electrical stimulation (BreEStim) to attempt to dampen autonomic changes that are thought to be associated with neuropathic pain. In short, BreEStim modulates the autonomic system, which is associated with the pain neuromatrix–central autonomic network, an area that has been shown to be partially responsible for mediating pain [
64‐
66]. The successful activation of the pain neuromatrix–central autonomic network can be quantified by looking at combined effects on autonomics as measured by heart rate variability [
67]. A small sample of patients post SCI completed a controlled trial in which the treatment group received 120 BreEStim impulses [
67]. The treatment group experienced a decrease in heart rate variability, indicating that BreEStim may provide for a viable treatment strategy for decreasing post-SCI pain [
67].
Individuals with CNP experience major decreases in quality of life secondary to not only pain but also a general decrease in motor and sensory function. Given the well-known importance of physical activity, a Japanese study group looked at a placebo-controlled study of the effect of exercise on neuropathic pain [
68,
69]. Exercise consisted of vigorous wheelchair propulsion while the patient was assessed by EEG [
68,
69]. The subject completed a subjective NRS for neuropathic pain and a profile of mood states [
68,
69]. Objectively, peak alpha frequencies were measured in four areas of the brain: frontal, central, parietal, and occipital [
68,
69]. In comparison to the control group, the SCI group showed significantly lower pre-wheelchair parietal and occipital peak alpha frequencies that have previously been shown to signify increased neuropathic pain [
68,
69]. Post-exercise central peak alpha frequencies were significantly higher in the SCI group and unchanged in the placebo group [
70]. Further, subjective measures of pain were shown to decrease and perceptions of mood were shown to increase following treatment [
70].